Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
174 Leser
Artikel bewerten:
(0)

Milestone Scientific, Inc.: Milestone Scientific Appoints Medical Device Veteran Brent W. Johnston as President

LIVINGSTON, NJ / ACCESSWIRE / September 4, 2019 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug instruments that provide painless and precise injections, today announced the appointment of Brent W. Johnston as President of Milestone Scientific. Mr. Johnston's responsibilities will include overseeing the global rollout of the CompuFlo Epidural System, as well as regulatory activities, production, and commercialization of the Company's products based on its proprietary DPS Dynamic Pressure Sensing technology.

Mr. Johnston is a senior level, medical device industry executive with over 25 years of experience in sales, marketing and organizational efficiency. He has brought a number of spine, orthopedic and other medical products to market. Prior to joining Milestone Scientific, Mr. Johnston served as Vice President of Sales at Clariance, a spinal device company, where he restructured the sales and marketing strategy for the US market. During his tenure at Clariance, he executed on growth strategies resulting in significant year-over-year growth. Previously, he served as Chief Executive Officer at ExsoMed, an upper extremity orthopedic company where he brought the company from start up to full commercialization. Mr. Johnston founded and served as Chief Operating Officer at Aurora Spine, Inc., where he grew the company from startup to full commercialization and oversaw the launch of 20 products. He was also a key member of the team to take the company public. He held senior executive roles at Phygen Spine and Lanx, Inc., where he was responsible for growing sales and launching new products. Mr. Johnston also founded and grew Corvus Medical, Inc., a company focused on products in spine, orthopedics, biologics and durable goods. Mr. Johnston received a Bachelor's degree in Political Science and Business Administration from Eastern Washington University and received a Masters in Business Administration from Norwich University.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, "Brent brings extensive experience in the medical device sector, including an impressive track record launching new commercial products, as well as driving both top and bottom-line growth for existing products. We are delighted to welcome him to the team at this exciting time for Milestone, as we accelerate our commercial efforts around the CompuFlo Epidural System having gained significant traction with key opinion leaders. We believe Brent will be an invaluable addition to the team."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.



View source version on accesswire.com:
https://www.accesswire.com/558382/Milestone-Scientific-Appoints-Medical-Device-Veteran-Brent-W-Johnston-as-President

© 2019 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.